(Q36623050)

15 August 2017

1 reference

title

Developments in the treatment of candidiasis: more choices and new challenges (English)

1 reference

15 August 2017

1 reference

Eleftherios Mylonakis

series ordinal

4

object named as

Eleftherios Mylonakis

1 reference

15 August 2017

George Aperis

1

1 reference

15 August 2017

Nikolaos Myriounis

series ordinal

2

1 reference

15 August 2017

Elias K Spanakis

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Expert Opinion on Investigational Drugs

15 August 2017

published in

1 reference

15 August 2017

volume

15

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

1319-1336

1 reference

Epidemiology of Candida species infections in critically ill non-immunosuppressed patients

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Update on antifungal treatment of invasive Candida and Aspergillus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Opportunistic candidiasis: an epidemic of the 1980s.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990-9).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Invasive Candida species infections: a 5 year population-based assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Attributable mortality of nosocomial candidemia, revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

The impact of candidemia on length of hospital stay, outcome, and overall cost of illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Nosocomial bloodstream infections in Finnish hospitals during 1999-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

The global epidemiology of invasive Candida infections--is the tide turning?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Comparison of the modified Stokes' method of susceptibility testing with results obtained using MIC methods and British Society of Antimicrobial Chemotherapy breakpoints.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/- knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Assessment of the paradoxical effect of caspofungin in therapy of candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Activities of flucytosine, fluconazole, amphotericin B, and micafungin in a murine model of disseminated infection by Candida glabrata

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Alternatives to amphotericin B for Candida rugosa infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Voriconazole salvage treatment of invasive candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in h

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1319

10.1517/13543784.15.11.1319

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference